



Veterinary  
Medicines  
Directorate

United Kingdom  
Veterinary Medicines Directorate  
Woodham Lane  
New Haw  
Addlestone  
Surrey KT15 3LS

**DECENTRALISED PROCEDURE**

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY  
MEDICINAL PRODUCT**

Cephacare Flavour 1000 mg Tablets for Dogs (UK, IE, LU, DE, AT, BE)  
Cephacare Sabor 1000 mg tablets for Dogs (ES, PT)  
Cephacare F 1000 mg tablets for dogs (FR)

Date Created: March 2017

**PuAR correct as of 16/04/2018 when RMS was transferred  
to IE. Please contact the RMS for future updates.**

## **MODULE 1**

### **PRODUCT SUMMARY**

EU Procedure number	UK/V/0251/004/DC
Name, strength and pharmaceutical form	Cephacare Flavour 1000 mg Tablets for Dogs
Applicant	Animalcare Ltd 10 Great North Way York Business Park Nether Poppleton York Yorkshire YO26 6RB
Active substance(s)	Cefalaxin monohydrate
ATC Vetcode	QJ01DB01
Target species	Dogs
Indication for use	Treatment of infections of the respiratory tract, gastro-intestinal tract, urogenital tract, the skin and localised infections in soft tissue caused by bacteria sensitive to cefalexin.

## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

[www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed)

## **MODULE 3**

### **PUBLIC ASSESSMENT REPORT**

Legal basis of original application	Generic application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
Date of conclusion of the decentralised procedure	21 December 2016
Date product first authorised in the Reference Member State (MRP only)	Not applicable
Concerned Member States for original procedure	Austria, Belgium, France, Germany, Ireland, Luxembourg, Portugal, Spain

#### **I. SCIENTIFIC OVERVIEW**

This application was for a line extension to add Cephacare Flavour 1000 mg tablets to the existing marketing authorisation for Cephacare Flavour 50, 250 and 500 mg tablets for cats and dogs. These tablets were authorised in December 2008. The original applications were submitted in accordance with Article 13(1) of EC Directive 2001/82/EC (as amended) citing Ceporex Vet 50, 250 and 500 mg tablets as the reference product.

The product is indicated for use in dogs for the treatment of infections of the respiratory tract, gastro-intestinal tract, urogenital tract, the skin and localised infections in soft tissue caused by bacteria sensitive to cefalexin.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released onto the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC.<sup>1</sup> The product is safe for the user and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy <sup>2</sup> of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

<sup>1</sup> SPC – Summary of product Characteristics.

<sup>2</sup> Efficacy – The production of a desired or intended result.

---

## **II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS**

### ***II.A. Composition***

The product contains 1000 mg cefalaxin as cefalaxin monohydrate and the excipients lactose monohydrate, potato starch, magnesium stearate and beef flavour.

The container/closure system consists of in PVC/PE/PVDC/Aluminum foil blister packs each containing 10 tablets, in cardboard boxes containing 100 or 250 tablets. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation is justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

### ***II.B. Description of the Manufacturing Method***

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of a simple mixing and compressing process.

The product is manufactured in accordance with the European Pharmacopoeia and relevant European guidelines.

### ***II.C. Control of Starting Materials***

The active substance is Cefalexin, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The active substance is supplied in accordance with a European Pharmacopoeia Certificate of Suitability.

Excipients, apart from the Beef Flavour, are the subject of monographs in the European Pharmacopoeia. Compliance with the requirements of the pharmacopoeia was therefore applied as the specification for each of these ingredients. The Beef Flavour complies fully with Directive 88/388/EC concerning labelling of foods flavours and meets an in-house specification.

#### ***II.C.4. Substances of Biological Origin***

Scientific data have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

#### ***II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process***

Not applicable.

#### ***II.E. Control Tests on the Finished Product***

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification. Control tests on the finished product include those for appearance, mass, uniformity, friability, crushing strength, identification, disintegration time, dissolution, microbial quality and water content.

#### ***II.F. Stability***

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

#### ***G. Other Information***

Shelf-life of the veterinary medicinal product as packaged for sale: 12 months

Return any ½ tablet to the blister pack and use within 48 hours.

Do not store above 25°C.

Store in a dry place.

Keep the blister in the outer carton.

---

### III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACO-TOXICOLOGICAL)

This application is a line extension of Cephacare Flavour 50, 250 and 500 mg tablets for cats and dogs by the addition of a higher strength tablet, Cephacare Flavour 1000 mg tablets for dogs. The original applications were submitted in accordance with Article 13(1) of Directive 2001/82/EC (as amended). No pharmacology or toxicology data were required.

#### ***User Safety***

A user risk assessment was provided in compliance with the relevant guideline which shows that there is a risk of sensitisation.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:

- Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillin may lead to cross-reactions to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious. Do not handle this product if you know you are sensitised or if you have been advised not to be in contact with such substances.
- Handle this product with great care to avoid exposure, taking all recommended precautions. If you develop symptoms following exposure such as skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.
- In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
- Wash hands after use.

#### ***Environmental Safety***

An environmental risk assessment (ERA) has been provided according to Phase I guideline (CVMP/VICH/592/98-FINAL) and the supporting CVMP technical guidance note (EMA/CVMP/ERA/418282/2005-Rev.1). The assessment terminated at question 3 of the VICH Phase I decision tree as the product is only intended for non-food animals and therefore no Phase II assessment is required.

No environmental warnings are proposed and the standard disposal advice is stated in section 6.6 of the SPC, 'Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.'

#### **IV CLINICAL DOCUMENTATION**

This application is a line extension of Cephacare Flavour 50, 250 and 500 mg tablets for cats and dogs by the addition of a higher strength tablet, Cephacare Flavour 1000 mg tablets for dogs. The original applications were submitted in accordance with Article 13(1) of Directive 2001/82 (as amended).

In the original application, *in vivo* bioequivalence between Cephacare Flavour 250 mg tablets and Ceporex Vet 250 mg tablets was demonstrated in the dog. The applicant further conducted *in vitro* dissolution studies to link the 500 mg and 50 mg Cephacare Flavour tablet sizes to the 250 mg tablet size.

The applicant has justified conducting a dissolution study to link the 1000 mg size Cephacare Flavour tablet to the other tablet strengths within the product range. The applicant provided adequate *in vitro* dissolution studies in compliance with the bioequivalence guideline EMA/CVMP/016/00-Rev 2 to demonstrate bioequivalence with the previously authorised products in the range.

#### **V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that <when the product is used in accordance with the Summary of Product Characteristics> the benefit/risk profile of the product(s) is favourable.



## **MODULE 4**

### **POST-AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

[www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

[www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed)